Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 20/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.68 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.68 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.68 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389409 | 0.92 | DHODH (0.81) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL4397456 | 0.85 | DHODH (0.84) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL4398588 | 0.83 | DHODH (0.63) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL3914908 | 0.82 | DHODH (0.77) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL29352865 | 0.81 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL25834765 | 0.81 | DHODH (0.84) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL247888 | 0.81 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL28322326 | 0.81 | DHODH (0.76) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL28974266 | 0.80 | DHODH (0.98) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL28323370 | 0.80 | DHODH (0.82) | DHODHNR4A2NR4A1JMJD7NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392642-B1 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2009-12-09 | — | — | EP | disclosed |